The FDA issued draft guidance aimed at sponsors developing individualized human genome editing products and preparing Biologics License Applications (BLAs) for personalized, rare-disease treatments. The document, “Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management” (FDA-2026-D-11783), lays out a regulatory framework for how an individualized genome-editing program could stay within a single BLA while allowing product variation across patients. Central to the draft is the concept of an “Individualized Feature Space (IFS),” defined as pre-established limits describing allowable variation for genome-edited components. For example, the agency discusses how an IFS could specify which classes of gRNA spacer sequences are acceptable for targeting defined pathogenic variants and producing a consistent editing outcome, potentially reducing the need for fresh clinical trials each time the therapy is personalized. The agency also opened a public comment period through Nov. 27. Market participants reacted positively, with Jefferies analyst Maury Raycroft describing “de-risking data & reg catalysts” and pointing to constructive FDA/gov signals as momentum support for gene editing companies. The guidance arrives alongside heavy data activity from the European Society of Gene and Cell Therapy’s ESGCT Congress in Hamburg, where developers presented additional editing-focused clinical and translational updates.